pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone.

Insurance 129

Insurance 129

Outsourcing Pharma

APRIL 14, 2022

The US agencyâs latest draft document lays out guidelines to help increase involvement of underrepresented ethnic and racial populations in clinical research.

Documentation 97

Documentation FDA 97

The Honest Apothecary

APRIL 15, 2022

Mark Cuban. The internet has been all astir for months about the entrance of billionaire Mark Cuban into the pharmacy market with his CostPlus pharmacy model – touted to save consumers money. His mission sounds altruistic enough, and I have even heard some describe his purpose as “philanthropic.” I have no bones to pick with a creative entrepreneur who has found a new way to make a buck.

52

52

SingleCare

APRIL 14, 2022

Any pharmacy technician will tell you that a day behind the counter is a busy one. Pharmacy techs can’t do every task that pharmacists do, but they handle a whopping list of duties during their long, on-their-feet-all-day shifts. They count pills, call insurance companies, staff the register and the drive-thru, verify insurance coverage, check inventory, and talk to doctor’s offices, all while answering phones, responding to customer questions and complaints, and sometimes even administering vac

Insurance 52

Insurance Insurance Coverage Communication Community Pharmacies 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 12, 2022

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category. The Department of Health, NHS England and NICE have completed an evaluation of two new antibiotics – Pfizer’s Zavicefta (ceftazidime/avibactam) and Shionogi’s Fetcroja (cefiderocol) – that will be paid for using the new subscription-like model likened to a Netflix account.

114

114

Outsourcing Pharma

APRIL 12, 2022

A recent online event hosted by the patient services company invited a number of women to share their experience and insights working in the research field.

95

95

Pharmig

APRIL 13, 2022

Everyone wants to know where they come from, and microbiologists are no different. But were we grown in a petri dish. The post The benefits of training in pharmaceutical microbiology appeared first on Pharmig.

52

52

pharmaphorum

APRIL 11, 2022

In an interview with Dudley Tabakin (CEO, VivoSense), Chris Garabedian (CEO, Xontogeny) and Tanja Dowe (CEO, Debiopharm Innovation Fund), pharmaphorum discusses the recent announcement of the closing of a $25 million Series A financing round to scale up the innovative VivoSense® software, which uses wearable sensor data in clinical trials, and for the development of novel digital biomarkers.

Pharmaceutical Companies 109

Pharmaceutical Companies Pharmaceutical Companies Packaging 109

Outsourcing Pharma

APRIL 12, 2022

Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.

87

87

Pharma Mirror

APRIL 12, 2022

There are so many ways to get into the healthcare industry these days. There are a lot of changes happening in the industry which means that there are a lot of niche services that you can provide and make a lot of money while also serving your communities needs. For instance, telehealth is a burgeoning field these days and is a good place to start. Another area that has a lot of potentials is starting a medical lab facility.

Medical Schools 52

Medical Schools 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

NICE

APRIL 12, 2022

Care models are changing all around us. The significant advancement of digital health technologies and artificial intelligence (AI) capabilities have the potential to revolutionise health and social care. A project within Gloucestershire Hospitals Trust is an excellent example of this. They used machine learning to identify patients at risk of avoidable long-term hospital stays.

Hospitals 52

Hospitals 52

pharmaphorum

APRIL 11, 2022

Janssen’s Catherine Taylor, vice-president, EMEA medical affairs, therapy area strategy, discusses the importance of systemic innovation across the healthcare system to realise the full value of medicines. Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world. As an oncology trained medical doctor who practiced in the UK NHS for 10 years, I have seen the benefits first-hand, as patients live longer lives, free from symp

Pharmaceutical Companies 108

Pharmaceutical Companies Pharmaceutical Companies Vaccines Packaging 108

Pharma Marketing Network

APRIL 12, 2022

Tune in to this episode of the Pharma Marketing Podcast for a deeper dive into pharma and modular content, with Ryan Rosenberg, Director Omnichannel Capabilities @ Sanofi , who shared his insights on making modular content work and why pharma is the perfect candidate for it. The post Ep. 21: Pharma & Modular Content: A Deeper Dive appeared first on Pharma Marketing Network.

52

52

Outsourcing Pharma

APRIL 13, 2022

An expert from trial tech specialist Komodo Health talks about how real-world evidence use could elevate study design, conserve costs, and improve recruitment.

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Med Ed 101

APRIL 13, 2022

I’ve done tons of posts on drug interactions over the years. I’ve dedicated a whole book to drug interactions in primary care AND drug-food interactions. I was recently asked about metoprolol drug interactions and which ones would I consider the most important? Here’s my list of metoprolol drug interactions that I think would be valid […].

45

45

pharmaphorum

APRIL 13, 2022

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech’s shares skywards. GSK is paying $55 per share in cash for Sierra – a 39% premium to its closing share price yesterday – which values the company at around $1.9 billion. Shares in Sierra were up 38% in pre-market trading this morning.

Vaccines 99

Vaccines 99

Berkeley Pharma Tech

APRIL 15, 2022

As of 2022, working within the pharmaceutical sector is one of the best ways to create a meaningful impact on society. Research, development, manufacturing, and prescribing medications are an integral part of the mission of the pharmaceutical industry which is to ultimately enhance the lives of many. There are also a wide variety of rewarding positions available in this field.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies 40

Outsourcing Pharma

APRIL 11, 2022

This monthâs news includes hiring, promotions, expansions, and acquisitions at H Clinical, Charles River, DHL Supply Chain, X-Chem, and other key companies.

52

52

Med Ed 101

APRIL 10, 2022

I started this blog to help educate healthcare professionals all the way back in 2013. It’s hard to believe that I’m approaching 10 years! I can’t thank you all enough for the support. Your purchases have helped me continue to do this blog and podcast while working part-time as a clinical pharmacist. I enjoy giving […]. The post New Release!

40

40

pharmaphorum

APRIL 11, 2022

GripAble has raised $11 million in first-round financing that will be used to advance its digital health approach to rehabilitation for people with neurological and musculoskeletal conditions on the international stage. The London, UK-based company has developed a platform that combines a hand-held sensor, gamified mobile app software, and telehealth consultations with therapists, which is designed to entertain users while they train at home.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharma Times

APRIL 12, 2022

Novacyt’s second direct-to-PCR test is the third product to be added to the Coronavirus Test Device Approvals (CTDA) register of approved products

37

37

Outsourcing Pharma

APRIL 11, 2022

The biomarker developer is partnering with Alzheimer Center Amsterdam on decentralized assessment of patient cognition and function in preclinical research.

52

52

pharmaphorum

APRIL 12, 2022

Cate Evans, SVP group director, strategy at Havas Media Group, and Nick Lapolla, research director at MedSurvey tell us about a two-phase research study the companies recently performed to understand a patient’s prescription journey and who influences prescription-based decisions. The healthcare landscape has shifted dramatically due to the pandemic.

Communication 98

Communication Patient Care FDA 98

pharmaphorum

APRIL 12, 2022

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase 1b data on JDQ443 showing efficacy in KRAS-mutated non-small cell lung cancer (NSCLC). The results – presented at the American Association of Cancer Research (AACR) congress – set Novartis off in pursuit of Amgen, whose Lumakras (sotorasib) is already on the market, and Mirati Therapeutics which has adagrasib under review by the FDA.

FDA 98

FDA 98

pharmaphorum

APRIL 13, 2022

Training can be a bore; dull, predictable sessions shoe-horned into the diary when a meeting room is available or via a virtual session full of muted moments and cross-talk confusion. The pharma industry has turned the microscope of every aspect of its delivery in the face of era-defining shifts caused by the pandemic, and now it is time focus on coaching staff to perform across a new sales and information-sharing landscape.

Communication 89

Communication Hospitals 89

pharmaphorum

APRIL 14, 2022

The massive backlog in patient care across Europe resulting from the pandemic will take at least three years to clear and in some cases as long as six years, says a new study. The research from Censuswide stems from surveys of oncologists and surgeons across six European countries, which found that 20% of them estimate clearing the backlog will take between four and six years.

Hospitals 78

Hospitals Patient Care 78

pharmaphorum

APRIL 14, 2022

Pfizer’s Australian unit has tabled an offer to buy ResApp Health and its smartphone apps for the management and diagnosis of respiratory diseases in a deal that values the digital health company at around A$100 million (around $75 million). Pfizer is offering A$0.115 per share in cash for ResApp, a deal which has been accepted by the company’s directors and recommended to shareholders ahead of a vote scheduled in June.

75

75

pharmaphorum

APRIL 14, 2022

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL). The drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a median duration of response of 12 months.

Immunization 64

Immunization 64

pharmaphorum

APRIL 14, 2022

US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1 million price tag. ICER’s assessment is still at the draft stage and could be changed after an ongoing comment period, but will be welcomed by bluebird and other gene therapy developers as they try to set a price for their one-shot treatments that will be accepted by payers.

FDA 64

FDA 64

pharmaphorum

APRIL 13, 2022

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s oral therapy Vumerity, after NICE recommended the drug for routine NHS use. The decision means that Vumerity (diroximel fumarate) – a follow-up to Biogen’s older oral therapy Tecfidera (dimethyl fumarate) – is now available to eligible patients across the UK, as the Scottish Medicines Consortium approved the drug in February.

Documentation 64

Documentation 64

pharmaphorum

APRIL 11, 2022

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphoma patients, although not for the version that will likely be filed for approval. The MD Anderson study now has data from 19 patients, with all responding and 13 (62%) having a complete response after treatment with AFM13.

Chemotherapy 59

Chemotherapy 59

pharmaphorum

APRIL 14, 2022

In a world of a million messages, should authenticity be the common thread tying all pharma communications and marketing activities together? Authentic, knowledgeable communications designed and executed by authentic, knowledgeable professionals is the key to pharma’s success in today’s media landscape. That’s according to the team at the world’s largest association of independent healthcare communications agencies, which has just rebranded from GLOBALHealthPR to Global Health Marketing & Co

Communication 52

Communication Vaccines 52

pharmaphorum

APRIL 14, 2022

Oligonucleotide Therapeutics and Delivery Conference 2022. Date: 21st – 22nd September 2022. Location: London, UK. Website: www.oligonucleotide.co.uk/pharmaphorum. Advancements in extra-hepatic delivery of oligonucleotides. The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances.

52

52

pharmaphorum

APRIL 13, 2022

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, its other drug in the class. The results reported at the American Association of Cancer Research (AACR) meeting are from the REFINE trial of navitoclax alongside Novartis and Incyte’s JAK inhibitor Jakafi (ruxolitinib) in 34 patients with myelofibrosis who had not responded well to Jakafi on its own

52

52